Europe Exosome Diagnostic and Therapeutic Market Size, Share & Industry Trends Analysis Report By Application (Diagnostic and Therapeutic), By Product (Reagent, Instrument, and Software), By End User, By Country and Growth Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Exosome Diagnostic and Therapeutic Market
Market Report Description
The Europe Exosome Diagnostic and Therapeutic Market would witness market growth of 26.2% CAGR during the forecast period (2022-2028).
Exosomes are nanovesicles that are part of an intercellular communication system. Their features appear potential as a biomarker in cancer research, which urgently requires more sophisticated monitoring and therapeutic applications. Overall survival in the case of head and neck squamous cell carcinoma (HNSCC) is generally poor, despite significant technological advances in the treatment of this illness. Diagnostic and therapeutic qualities are highlighted and summarized in the following review. Although the initial results are promising, additional research is needed before these revolutionary procedures can be implemented into daily clinical practice.
Exosomes had been widely dismissed as a form of cellular trash and had been forgotten for decades. When their capabilities for intercellular communication, involvement with the immune system, and potential use as a drug vector were discovered, everything changed. The precise definition of exosomes has sparked a lot of debate to date.
In Europe, cardiovascular diseases (CVD) continue to be the primary cause of death, accounting for 45 percent of all deaths. Every year, more than 4 million Europeans die from cardiovascular disease (CVD), primarily from CHD and stroke. Many more are admitted to hospitals, and many more acquire long-term disabilities that necessitate lifetime therapy. CVD has huge economic ramifications for Europe, in addition to human misery. CVD is predicted to cost the EU economy €210 billion per year, which includes direct health-care expenditures as well as non-health costs such as lost productivity and informal care for people with CVD. The cardiovascular disease mortality rate in Central and Eastern Europe is the highest in the world.
The Germany market dominated the Europe Exosome Diagnostic and Therapeutic Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $96.9 million by 2028. The UK market is estimated to grow at a CAGR of 25.2% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 27.2% during (2022 - 2028).
Based on Application, the market is segmented into Diagnostic and Therapeutic. Based on Product, the market is segmented into Reagent, Instrument, and Software. Based on End User, the market is segmented into Cancer Institute, Hospital, Diagnostic Center, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Aethlon Medical, Inc., Capricor Therapeutics, Inc., Malvern Panalytical Ltd., NanoSomix, Inc., System Biosciences, LLC, and NX Pharmagen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
- Cancer Institute
- Diagnostic Center
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Bio-Techne Corporation
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Aethlon Medical, Inc.
- Capricor Therapeutics, Inc.
- Malvern Panalytical Ltd.
- NanoSomix, Inc.
- System Biosciences, LLC
- NX Pharmagen, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free